Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 combined with adebrelimab in previously treated advanced NSCLC
ChiCTR2400086362Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tizetatug rezetecan and adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
tizetatug rezetecanadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086362.